Photo by nci from unsplash
Key Points Question Is statin use during androgen-ablative therapies (androgen deprivation or androgen receptor axis–targeted therapies) associated with reduced mortality among men with prostate cancer? Findings In this systematic review… Click to show full abstract
Key Points Question Is statin use during androgen-ablative therapies (androgen deprivation or androgen receptor axis–targeted therapies) associated with reduced mortality among men with prostate cancer? Findings In this systematic review and meta-analysis of 25 cohorts including 119 878 men, concurrent statin use was associated with a 27% reduced risk of overall mortality and a 35% reduced risk of prostate cancer–specific mortality. Meaning These findings suggest that concurrent statin use may improve survival in men receiving androgen-ablative therapies for advanced prostate cancer; randomized clinical trials are warranted to confirm these findings.
Journal Title: JAMA Network Open
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!